Significant Relationship of Matrix Metalloproteinase 9 with Nuclear Grade and Prognostic Impact of Tissue Inhibitor of Metalloproteinase 2 for Incidental Clear Cell Renal Cell Carcinoma

Urology

Volumn 69, Issue 6, 2007, Pages 1049-1053

  Kawata, Nozomu ^a   Nagane, Yusuke ^a   Hirakata, Hitoshi ^a   Ichinose, Taketo ^a   Okada, Yasuhiro ^a   Yamaguchi, Kenya ^a   Takahashi, Satoru ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENTAL FINDING; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 34250016570     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.02.044     Document Type: Article

References (26)

1. Skinner D.G., Colvin R.B., Vermillion C.D., et al. Diagnosis and management of renal cell carcinoma: a clinical and pathological study of 309 cases. Cancer 28 (1971) 1165-1177
2. Konnak J.W., and Grossman H.B. Renal cell carcinoma as an incidental finding. J Urol 134 (1985) 1094-1096
3. Ficarra V., Galetti-Prayer T., Novella G., et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 43 (2003) 663-669
4. Hellsten S., Johnson J., Berg T., et al. Clinically unrecognized renal cell carcinoma. Eur Urol 18 suppl (1990) 2-3
5. Mindrup S.R., Pierre J., Dahmoush L., et al. The prevalence of renal cell carcinoma diagnosed at autopsy. BJU Int 95 (2005) 31-33
6. Patard J.J., Leray E., Cindolo L., et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 172 (2004) 858-862
7. Ficarra V., Galetti-Prayer T., Novara G., et al. Tumor-size breakpoint for prognostic stratification of localized renal cell carcinoma. Urology 63 (2004) 235-240
8. Jeong I.G., Jeong C.W., Hong S.K., et al. Prognostic implication of capsular invasion without perinephric fat infiltration in localized renal cell carcinoma. Urology 67 (2006) 709-712
9. Kawata N., Nagane Y., Igarashi T., et al. Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma. Urology 68 (2006) 523-527
10. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
11. Sobin L.H., and Wittekind C. TNM Classification of Malignant Tumours. 6th ed (2002), John Wiley & Sons, New York
12. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663
13. Lang H., Lindner V., Saussine C., et al. Microscopic venous invasion: a prognostic factor in renal cell carcinoma. Eur Urol 38 (2000) 600-605
14. Chambers A.F., and Matrisian L.M. Changing view of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
15. Zucker S., Hymowitz M., Conner C., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissue: clinical and experimental applications. Ann NY Acad Sci 878 (1999) 212-227
16. Gohji K., Fujimoto N., Komiyama T., et al. Evaluation of serum levels of matrix metalloproteinases-2 and 3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78 (1996) 2379-2387
17. Grignon D.J., Sakr W., Toth M., et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56 (1996) 1654-1659
18. Alexander C.M., and Werb Z. Targeted disruption of the tissue inhibitor of metalloproteinase gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro. J Cell Biol 118 (1992) 727-739
19. Declerck Y.A., Peres N., Shimada H., et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52 (1992) 701-708
20. Kallakury B.V., Karikehalli S., Haholu A., et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7 (2001) 3113-3119
21. Ree A.H., Florenes V.A., Berg J.P., et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastasis. Clin Cancer Res 3 (1997) 1623-1628
22. Grignon D.J., Sakr W., Toth M., et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56 (1996) 1654-1659
23. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
24. Yagasaki H., Kawata N., Takimoto Y., et al. Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 10 (2003) 220-227
25. Yoshiji H., Harris S.R., Raso E., et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinase-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75 (1998) 81-87
26. Awakura Y., Ito N., Nakamura E., et al. Matrix metalloproteinase-9 polymorphism and renal cell carcinoma in Japanese population. Cancer Lett 20 (2006) 1-5